Opportunism Knocks
This article was originally published in Start Up
Executive Summary
In this era of pharmaceutical industry consolidation, large pharmaceutical companies, and in particular the newly-merged, taking stock of their increasing bulk, have been heard to say that they will drop products in development that don't have the potential to achieve at least $500 million in revenues. Big pharmas are also looking more critically at their small products already on the market. For these large companies, small products could prove to be a distraction that diverts resources away from potential blockbusters, the kinds of products that the companies will need to grow by 15% a year going forward. In theory, then, as pharmaceutical companies up-average product portfolios in favor of high-revenue producers and prune away redundant or non-strategic products in the aftermath of mergers, many more commercializable products should become available for licensing than ever before. That is the hope, anyway, of a handful of new specialty pharmaceutical companies formed to acquire on-the-market products with the aim of growing their sales through a variety of strategies. These companies avoid product development risk but bear risk of a different sort. To be successful, they must be able to continually acquire products that can grow, and not pay too much for them.
You may also be interested in...
MedPointe and Opportunities in Specialty Pharma: Speed is Expensive
The notion of building up a new drug company with the unwanted, undersized products of ever-bigger Big Pharma is hardly new. But MedPointe, with its acquisition of Carter Wallace's medical products business, is aiming to build up a new firm faster and bigger than can be done simply by in-licensing.
Shire Shifts Upstream
Shire's latest acquisition, of Canada's BioChem Pharma, is its sixth in as many years, and the clearest sign yet of the shift which the UK-based specialty pharmaceutical company has to make towards earlier-stage research in order to keep up its impressive growth. Behind this growth is its low-risk Search & Development strategy: it seeks out promising, undervalued specialist-market drugs which it develops for new indications, or else finds new formulations for, after which it hands them on to its highly focused marketing and sales teams. A series of acquisitions-bolting on products, development programs and skills-has allowed Shire to quickly expand globally and broaden its portfolio. But as drugs get harder to find and more expensive, the company has had to throw its S&D net wider.
Bergen Brunswig Gets Out Of the Specialty Retail Business
Bergen Brunswig Corp's recent announcement that it would sell the specialty pharmacy assets of its Stadtlander Drug Co. subsidiary hardly comes as a surprise. Stadtlander has performed poorly since it was acquired from Counsel Corp. eighteen months ago. Stadtlander is not alone: two other Bergen subsidiaries, PharMerica (which distributes drugs to long-term care facilities) and Bergen Brunswig Medical Corp., a supply business (which is also being sold), have also disappointed.If Bergen's expectations for Stadtlander were not met, say company officials, it was because Counsel's management misled them with respect to the specialty pharmacy's value. Indeed, Bergen sued Counsel, alleging that it was fraudulently induced into paying the price that it did for Stadtlander. That case is pending.So far, investors and analysts have reacted favorably to the Stadtlander sale. In addition to reducing Bergen's debt and eliminating a drag on earnings, parting with Stadtlander is seen as a way for Bergen to refocus its attentions on its core drug distribution business.